Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

Inclusion Criteria: * Have unstable angina or NSTEMI,or stable angina with at least 2 factors indicating a high risk PCI as follows: patient related: diabetic patients, renal failure (glomerular filtration rate \< 60), reduced left ventricular ejection fraction \< 35%, age \> 75 years, female gender and/or lesion/anatomy related: SYNTAX score \> 26, bifurcation lesions, multi-vessel disease, intracoronary thrombus. * Adequate hematological function including platelets \> 100000/mm3. * Body mass index (BMI) ≥18 kg/m2 and ≤ 35 kg/m2. * Aged ≥ 18 years old. * Women of childbearing potential must be practicing a medically acceptable contraceptive regimen. Only males who do not want to father children during the study and in the first 4 months after treatment may be included in the study. During this period, safe contraception is mandatory. Male patients who are sexually active must use a condom during intercourse and ensure that the female partner uses a reliable contraceptive method, or they must refrain from sexual intercourse during the first 4 months after treatment. * Patients must be accessible for follow-up. * Have a sufficient command to read and understand all instructions necessary for giving informed consent and participating in the study. * Have signed and dated written informed consent prior to any study-related procedures. Exclusion Criteria: * Previous (within 30 days) treatment with GPIIb/IIIa inhibitors (such as ReoPro®). * ST-elevation myocardial infarction (…